DISTINGUISHING FEATURES OF MUSCULOSKELETAL SYSTEM EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE by Zhdan V. M., Kyrian O. A., Babanina M. Yu., Shilkina L. M., Katerenchuk O. I.

“…Therefore, the purpose of our research was to investigate the distinguishing features of the spine and joints lesions in patients with ulcerative colitis (UC) and Crohn’s disease (CD), which are the most frequent extraintestinal manifestations of the forenamed diseases, and to investigate the possible link between the gut microbiota dysbiosis and the disease activity. …”
Get full text

Genomic insights from Paraclostridium bifermentans HD0315_2: General features and pathogenic potential by Hailan Zhao, Hailan Zhao, Jiaqi Wang, Jiaqi Wang, Yao Peng, Xunchao Cai, Yandi Liu, Yandi Liu, Wenqi Huang, Wenqi Huang, Hongli Huang, Hongli Huang, Yuqiang Nie, Yuqiang Nie

“…Herein, we reported the complete genome sequence of P. bifermentans HD0315_2 isolated from the feces of a patient with Crohn's disease. Then, we performed genomic analyses to understand its pathogenic mechanisms and adaptation ability.ResultsThe de novo assembly revealed that the HD0315_2 strain carried a circular chromosome of 3.27 Mb and six circular plasmids (19.41 to 139.50 kb). …”
Get full text

The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management by Ali Nabavi-Rad, Amir Sadeghi, Hamid Asadzadeh Aghdaei, Abbas Yadegar, Sinéad Marian Smith, Mohammad Reza Zali

“…Due to the lack of long-term follow-up studies to determine the efficiency of probiotic intervention in H. pylori eradication, and the delicate interaction of the gut microbiota with the host wellness, this review aims to discuss the gut microbiota alteration by probiotic co-supplementation in H. pylori management to predict the comprehensive effectiveness of probiotic oral administration.Abbreviations: acyl-CoA- acyl-coenzyme A; AMP- antimicrobial peptide; AMPK- AMP-activated protein kinase; AP-1- activator protein 1; BA- bile acid; BAR- bile acid receptor; BCAA- branched-chain amino acid; C2- acetate; C3- propionate; C4- butyrate; C5- valeric acid; CagA- Cytotoxin-associated gene A; cAMP- cyclic adenosine monophosphate; CD- Crohn’s disease; CDI- C. difficile infection; COX-2- cyclooxygenase-2; DC- dendritic cell; EMT- epithelial-mesenchymal transition; FMO- flavin monooxygenases; FXR- farnesoid X receptor; GPBAR1- G-protein-coupled bile acid receptor 1; GPR4- G protein-coupled receptor 4; H2O2- hydrogen peroxide; HCC- hepatocellular carcinoma; HSC- hepatic stellate cell; IBD- inflammatory bowel disease; IBS- irritable bowel syndrome; IFN-γ- interferon-gamma; IgA immunoglobulin A; IL- interleukin; iNOS- induced nitric oxide synthase; JAK1- janus kinase 1; JAM-A- junctional adhesion molecule A; LAB- lactic acid bacteria; LPS- lipopolysaccharide; MALT- mucosa-associated lymphoid tissue; MAMP- microbe-associated molecular pattern; MCP-1- monocyte chemoattractant protein-1; MDR- multiple drug resistance; mTOR- mammalian target of rapamycin; MUC- mucin; NAFLD- nonalcoholic fatty liver disease; NF-κB- nuclear factor kappa B; NK- natural killer; NLRP3- NLR family pyrin domain containing 3; NOC- N-nitroso compounds; NOD- nucleotide-binding oligomerization domain; PICRUSt- phylogenetic investigation of communities by reconstruction of unobserved states; PRR- pattern recognition receptor; RA- retinoic acid; RNS- reactive nitrogen species; ROS- reactive oxygen species; rRNA- ribosomal RNA; SCFA- short-chain fatty acids; SDR- single drug resistance; SIgA- secretory immunoglobulin A; STAT3- signal transducer and activator of transcription 3; T1D- type 1 diabetes; T2D- type 2 diabetes; Th17- T helper 17; TLR- toll-like receptor; TMAO- trimethylamine N-oxide; TML- trimethyllysine; TNF-α- tumor necrosis factor-alpha; Tr1- type 1 regulatory T cell; Treg- regulatory T cell; UC- ulcerative colitis; VacA- Vacuolating toxin A.…”
Get full text

FÍSTULA AORTO-DUODENAL NA DOENÇA DE HODGKIN by LLA Silva, AA Hofmann, RS Ferrelli, VR Siqueira, V Predebon, F Dortzbacher, XH Condori, ET Calvache, AA Paz, DH Catelli

“…Relato de Caso: Paciente feminina, 39 anos, com história prévia de Doença de Crohn colônica estenosante e perianal, vinha em acompanhamento com gastroenterologia ambulatorialmente, com bom controle da doença. …”
Get full text

THE FREQUENCY AND SEVERITY OF EXTRASKELETAL MANIFESTATIONS OF ANKYLOSING SPONDYLITIS by A. A. Godzenko, A. G. Bochkova, O. A. Rumyantseva, Yu. O. Korsakova, I. Yu. Razumova, V. V. Badokin, Sh. F. Erdes

“…IBD (ulcerative colitis or Crohn's disease) was diagnosed in 16 (3.5%) patients, including 4 who showed a severe course. 79 (36%) patients were observed to have a concurrence of two or more ESMs; that of uveitis and heart disease was most commonly seen. …”
Get full text

Therapeutic Potential of Triptolide as an Anti-Inflammatory Agent in Dextran Sulfate Sodium-Induced Murine Experimental Colitis by Bufu Tang, Bufu Tang, Jinyu Zhu, Jinyu Zhu, Baohui Zhang, Fazong Wu, Fazong Wu, Yajie Wang, Yajie Wang, Qiaoyou Weng, Shiji Fang, Liyun Zheng, Yang Yang, Yang Yang, Rongfang Qiu, Rongfang Qiu, Minjiang Chen, Minjiang Chen, Min Xu, Min Xu, Zhongwei Zhao, Zhongwei Zhao, Jiansong Ji, Jiansong Ji

“…Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is a group of chronic and incurable inflammatory diseases involving the gastrointestinal tract. …”
Get full text

INFLAMMATORY BOWEL DISEASE CARE IN BRAZIL: HOW IT IS PERFORMED, OBSTACLES AND DEMANDS FROM THE PHYSICIANS’ PERSPECTIVE by Eduardo Garcia VILELA, Henrique Carvalho ROCHA, Antônio Carlos MORAES, Genoile Oliveira SANTANA, José Miguel PARENTE, Ligia Yukie SASSAKI, Sender Jenkiel MISZPUTEN, Abel Botelho QUARESMA, Ana Paula Hamer Sousa CLARA, Adélia Carmen Silva de JESUS, Arlene dos Santos PINTO, Bianca Loyo Pona Schiavetti da SILVA, Bruno César da SILVA, Caio César Furtado FREIRE, Carlos Henrique Marques dos SANTOS, Carlos BRITO, Ellen Francioni Lima TEIXEIRA, Eron Fabio MIRANDA, Gilmara Pandolfo ZABOT, Jozelda Lemos DUARTE, Juliano Coelho LUDVIG, Luiz Felipe de CAMPOS-LOBATO, Ornella Sari CASSOL, Mardem Machado de SOUZA, Neogélia Pereira de ALMEIDA, Rogério Serafim PARRA, Sérgio Figueiredo de LIMA JÚNIOR, Rogério SAAD-HOSSNE

“…Infliximab and adalimumab were the most commonly used biological medicines and there was a higher prescription of 5-ASA derivatives for ulcerative colitis than for Crohn’s disease. Steroids were prescribed to a smaller proportion of patients in both diseases. …”
Get full text

Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21) by Joyce W. Y. Mak, Yang Sun, Julajak Limsrivilai, Murdani Abdullah, Jamilya Kaibullayeva, Domingo Balderramo, Beatriz Iade Vergara, Mukesh Sharma Paudel, Rupa Banerjee, Ida Hilmi, Raja Affendi Raja Ali, Shu Chen Wei, Ka Kei Ng, Mansour Altuwaijri, Paul Kelly, Jesus K. Yamamoto-Furusho, Paulo Gustavo Kotze, Vineet Ahuja, Vui Heng Chong, Hang Viet Dao, Yvonne Abbey, Jessica Y. L. Ching, Agnes Ho, Alicia K. W. Chan, Charles N. Bernstein, Richard B. Gearry, Maria Abreu, David T. Rubin, Iris Dotan, Lindsay Hracs, Gilaad G. Kaplan, Siew C. Ng, On behalf of the GIVES-21 Consortium

“…Methods Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) is a population-based cohort of newly diagnosed persons with Crohn’s disease and ulcerative colitis in Asia, Africa, and Latin America to be followed prospectively for 12 months. …”
Get full text

Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease by Charlotte Lichnog, Sha Klabunde, Emily Becker, Franklin Fuh, Philipp Tripal, Raja Atreya, Entcho Klenske, Rich Erickson, Henry Chiu, Chae Reed, Shan Chung, Clemens Neufert, Imke Atreya, Jacqueline McBride, Markus F. Neurath, Sebastian Zundler

“…The anti-β7 integrin antibody etrolizumab is currently being investigated for safety and efficacy in Crohn’s disease (CD) and ulcerative colitis (UC) in several phase III trials. …”
Get full text

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists by Tamara Pérez-Jeldres, Tamara Pérez-Jeldres, Tamara Pérez-Jeldres, Christopher J. Tyler, Christopher J. Tyler, Joshua D. Boyer, Joshua D. Boyer, Thangaraj Karuppuchamy, Thangaraj Karuppuchamy, Andrés Yarur, Daniel A. Giles, Shaila Yeasmin, Luke Lundborg, William J. Sandborn, Derek R. Patel, Jesús Rivera-Nieves, Jesús Rivera-Nieves

“…Tofacitinib, a JAK inhibitor targeting predominantly JAK1 and JAK3, has been approved for the treatment of ulcerative colitis (UC), and there are other specific JAK inhibitors under development that may be effective in Crohn’s. Similarly, the traffic of lymphocytes can now be targeted by another SM. …”
Get full text

Addition of hyperbaric oxygen therapy versus usual care alone for inflammatory bowel disease: A systematic review and meta-analysis by Jiu-hong You, Jun-liang Jiang, Wen-bo He, Hui Ma, Mei Zhou, Xin-xin Chen, Qiao-ling Liu, Cheng Huang

“…Objective: Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disease that includes ulcerative colitis (UC) and Crohn's disease (CD). Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a pressurized environment. …”
Get full text

Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease by Manon de Krijger, Thijmen Visseren, Manon E. Wildenberg, Gerrit K.J. Hooijer, Monique M.A. Verstegen, Luc J.W. van der Laan, Wouter J. de Jonge, Joanne Verheij, Cyriel Y. Ponsioen

“…Only patients with concomitant IBD were included (89% ulcerative colitis and 11% Crohn’s disease). Expression and distribution of MAdCAM-1, VAP-1, integrin β7, CCL25, CCL28, CXCL12, αE (CD103) and E-cadherin were assessed in both liver and colon tissue. …”
Get full text

Using real-world evidence data and digital monitoring to analyze the hepatotoxic profiles of biologics across more than two million patients by Priyanka Banerjee, Saskia Preissner, Robert Preissner

“…The primary objective was to assess the potential adverse hepatotoxic effects of the six biologics; adalimumab, trastuzumab, prevnar13, pegfilgrastim, interferon-beta1a and insulin glargine across different indications like diabetes mellitus, encounter for immunization, malignant neoplasm of breast, multiple sclerosis, malignant neoplasm of kidney, aplastic anaemias, radiation sickness, Crohn's disease, psoriasis, rheumatoid arthritis, spondylopathies. …”
Get full text

Multiplexed proteomics of autophagy-deficient murine macrophages reveals enhanced antimicrobial immunity via the oxidative stress response by Timurs Maculins, Erik Verschueren, Trent Hinkle, Meena Choi, Patrick Chang, Cecile Chalouni, Shilpa Rao, Youngsu Kwon, Junghyun Lim, Anand Kumar Katakam, Ryan C Kunz, Brian K Erickson, Ting Huang, Tsung-Heng Tsai, Olga Vitek, Mike Reichelt, Yasin Senbabaoglu, Brent Mckenzie, John R Rohde, Ivan Dikic, Donald S Kirkpatrick, Aditya Murthy

“…Loss-of-function of the core autophagy gene Atg16l1 increases risk for Crohn’s disease in part by enhancing innate immunity through myeloid cells such as macrophages. …”
Get full text

Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients by Hanan Alatawi, Mahmoud Mosli, Omar I. Saadah, Vito Annese, Rashad Al-Hindi, Marfat Alatawy, Hadba Al-Amrah, Dikhnah Alshehri, Ahmad Bahieldin, Sherif Edris

“…Stool samples were collected from a cohort of patients with an established diagnosis of IBD, either ulcerative colitis (UC) or Crohn’s disease (CD), following completion of the induction phase of anti TNF therapy. 16S rRNA sequencing analysis was used to examine the pattern of microbiota communities in fecal samples. …”
Get full text

The Pregnane X Receptor and Indole-3-Propionic Acid Shape the Intestinal Mesenchyme to Restrain Inflammation and FibrosisSummary by Kyle L. Flannigan, Kristoff M. Nieves, Holly E. Szczepanski, Alex Serra, Joshua W. Lee, Laurie A. Alston, Hena Ramay, Sridhar Mani, Simon A. Hirota

“…In biopsies from patients with active Crohn’s disease (CD) and ulcerative colitis (UC), expression of NR1I2 was reduced, correlating with increased expression of fibrotic and innate immune genes. …”
Get full text

Genetic analysis of normal human phenotypes within the people of the British Isles by Meena, D

“…<p>Genome-wide association studies have been of fundamental use in identifying common risk alleles with modest effects underlying multifactorial diseases such as diabetes, cancer, Crohn's disease as well as in polygenic traits, such as pigmentation, involving multiple genes. …”

Dietary palmitoleic acid reprograms gut microbiota and improves biological therapy against colitis by Yiwei Chen, Qiongdan Mai, Zixu Chen, Tao Lin, Yongjie Cai, Jing Han, Ying Wang, Mudan Zhang, Shimin Tan, Zhiying Wu, Lingming Chen, Zhiyi Zhang, Yi Yang, Taimei Cui, Beiyin Ouyang, Yue Sun, Lijia Yang, Lin Xu, Sien Zhang, Jian Li, Hongbo Shen, Linna Liu, Lingchan Zeng, Shenghong Zhang, Gucheng Zeng

“…Ex vivo treatment with POA in cultured inflamed colon tissues derived from Crohn’s disease (CD) patients reduced pro-inflammatory signaling/cytokines and conferred appreciable tissue repairment. …”
Get full text

Study of Environmental Enteropathy and Malnutrition (SEEM) in Pakistan: protocols for biopsy based biomarker discovery and validation by Najeeha T. Iqbal, Sana Syed, Kamran Sadiq, Marium N. Khan, Junaid Iqbal, Jennie Z. Ma, Fayaz Umrani, Sheraz Ahmed, Elizabeth A. Maier, Lee A. Denson, Yael Haberman, Monica M. McNeal, Kenneth D. R. Setchell, Xueheng Zhao, Shahida Qureshi, Lanlan Shen, Christopher A. Moskaluk, Ta-Chiang Liu, Omer Yilmaz, Donald E. Brown, Michael J. Barratt, Vanderlene L. Kung, Jeffrey I. Gordon, Sean R. Moore, S. Asad Ali

“…Histopathological changes in duodenal biopsies will be compared with duodenal biopsies obtained from USA controls who have celiac disease, Crohn’s disease, or who were found to have normal histopathology. …”
Get full text

Interleukin 36 receptor-inducible matrix metalloproteinase 13 mediates intestinal fibrosis by Kristina Koop, Karin Enderle, Miriam Hillmann, Laura Ruspeckhofer, Michael Vieth, Gregor Sturm, Zlatko Trajanoski, Zlatko Trajanoski, Anja A. Kühl, Anja A. Kühl, Raja Atreya, Raja Atreya, Moritz Leppkes, Patrick Baum, Janine Roy, Andrea Martin, Markus F. Neurath, Markus F. Neurath, Clemens Neufert, Clemens Neufert

“…BackgroundFibrostenotic disease is a common complication in Crohn’s disease (CD) patients hallmarked by transmural extracellular matrix (ECM) accumulation in the intestinal wall. …”
Get full text